- Previous Close
246.40 - Open
246.20 - Bid 235.25 x --
- Ask 236.90 x --
- Day's Range
234.30 - 246.20 - 52 Week Range
132.55 - 325.00 - Volume
15,353 - Avg. Volume
14,953 - Market Cap (intraday)
7.729B - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
18.02 - EPS (TTM)
13.09 - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 29, 2010
- 1y Target Est
--
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
www.wanbury.com1,491
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: WANBURY.BO
View MorePerformance Overview: WANBURY.BO
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WANBURY.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WANBURY.BO
View MoreValuation Measures
Market Cap
7.73B
Enterprise Value
9.40B
Trailing P/E
18.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.43
Price/Book (mrq)
19.95
Enterprise Value/Revenue
1.66
Enterprise Value/EBITDA
10.11
Financial Highlights
Profitability and Income Statement
Profit Margin
7.74%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.67B
Net Income Avi to Common (ttm)
439.07M
Diluted EPS (ttm)
13.09
Balance Sheet and Cash Flow
Total Cash (mrq)
117.47M
Total Debt/Equity (mrq)
466.42%
Levered Free Cash Flow (ttm)
--